WO2015112505 GOBLET CELL REPLACEMENT THERAPY

Settings

Stemming

Single Family Member

Include NPL

Feedback

Goto Application

Publication Number WO/2015/112505

Publication Date 30.07.2015

International Application No. PCT/US2015/012062

International Filing Date 20.01.2015

IPC

CPC

View more classifications

View less classifications

Applicants

UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US]/[US]

Inventors

YATES-BINDER, Cecelia, C.
WELLS, Alan, H.
SCHUMAN, Joel, S.
CONNER, Ian, P.

Agents

CONNOLLY, Jodi, L.

Priority Data

61/929,654

21.01.2014

Publication Language English (en)

Filing Language English (EN)

Designated States

View all

Title

(EN) GOBLET CELL REPLACEMENT THERAPY

(FR) TRAITEMENT DE REMPLACEMENT DES CELLULES CALICIFORMES

Abstract

(EN) Described herein is the finding that activators of CXCR3, such as proteins that bind CXCR3 (e.g., IP-9, IP-10 and PF4), enhance the density of goblet cells in the eye. Goblet cells in the conjunctiva are the primary source of tear mucus. Accordingly, the present disclosure describes methods of treating dry eye syndrome by administering an activator of CXCR3. Also described are methods of increasing goblet cells density, such as goblet cell density in the conjunctiva.

(FR) L'invention concerne la découverte selon laquelle des activateurs de CXCR3, par exemple des protéines qui se lient à CXCR3 (par exemple IP-9, IP-10 et PF4), améliorent la densité des cellules caliciformes de l'œil. Les cellules caliciformes de la conjonctive constituent la principale source de mucus lacrymal. L'invention concerne des méthodes permettant de traiter le syndrome de sécheresse oculaire en administrant un activateur de CXCR3. L'invention concerne également des méthodes permettant d'augmenter la densité des cellules caliciformes, par exemple la densité des cellules caliciformes de la conjonctive.

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38	Medicinal preparations containing peptides
16	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17	from animals; from humans
19	Cytokines; Lymphokines; Interferons

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
P	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27	Drugs for disorders of the senses
02	Ophthalmic agents
06	Antiglaucoma agents or miotics

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
P	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27	Drugs for disorders of the senses
02	Ophthalmic agents

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
P	SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27	Drugs for disorders of the senses
02	Ophthalmic agents
04	Artificial tears; Irrigation solutions

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38	Medicinal preparations containing peptides
16	Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17	from animals; from humans
19	Cytokines; Lymphokines; Interferons

Processing

National Phase Entries

Authority File

Settings

Feedback

Goto Application

1. WO2015112505 - GOBLET CELL REPLACEMENT THERAPY

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51	the non-active ingredient being a modifying agent
56	the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59	obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
60	the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51	the non-active ingredient being a modifying agent
56	the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
61	the organic macromolecular compound being a polysaccharide or a derivative thereof

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9	Medicinal preparations characterised by special physical form
0012	Galenical forms characterised by the site of application
0048	Eye, e.g. artificial tears

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47	Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50	the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51	the non-active ingredient being a modifying agent
56	the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59	obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
60	the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol